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=========

Steadying the ship through rough and uncharted waters {#sec1.1}
-----------------------------------------------------

Rather than filling a ballroom in National Harbor, MD, delegates to the APhA House engaged from their living rooms or makeshift offices, most likely wearing comfortable pants. Below is a summary of the policies that were passed by this year's APhA House of Delegates from the perspective of a practitioner and member of APhA--APPM.

Protecting pharmaceuticals as a strategic asset {#sec1.2}
-----------------------------------------------

With nearly 3.8 million prescription medications filled at a pharmacy in 2019, it is imperative that our pharmaceutical supply chain remains safe.[@bib1] However, it remains vulnerable to multiple threats, which can undermine patient access to life-sustaining medications. For example, nearly 40% of the finished drugs and 80% of the active pharmaceutical ingredients are manufactured overseas.[@bib2] In the setting of a global pandemic, it becomes increasingly difficult to ensure continued manufacturing and transport of these ingredients from the source countries. Furthermore, our own domestic supply chain is equally vulnerable.

Hurricane Maria was able to exacerbate an existing shortage of 0.9% sodium chloride when it destroyed parts of Puerto Rico in 2017.[@bib3] Drug shortages can also occur as a result of countless other problems. Throughout 2019 and in the first quarter of 2020, more than 250 active national drug shortages have been consistently listed, even before coronavirus disease (COVID--19) entered our lives.[@bib4] In our current pharmaceutical supply chain setup, there is minimal room for error with no intentional redundancies to help safeguard our nation's supply of necessary medications. This is a substantial public health and national security issue that requires urgent attention and action.

Accountability of pharmacists {#sec1.3}
-----------------------------

As pharmacists' roles on health care teams continue to expand, it is extremely important to address the issue of accountability. For example, collaborative practice agreements have been instrumental in delegating authority to pharmacists. In this collaboration, it is equally important for pharmacists to not only accept the privileges, but also to accept the accountability for their clinical decision-making. Pharmacists' undertook an oath to assure optimal outcomes for patients. However, unintentional adverse effects are unavoidable, and it is important that pharmacists accept accountability for those.

A concern introduced by our delegation was that the first statement might have been inadvertently too broad. Although we agreed with the sentiment, we felt that the clarifier "within their role on the health care team" was necessary at the end of the statement to keep it focused on only the elements over which a pharmacist has direct oversight. We supported the concept that pharmacists' professional accountability should accompany increased responsibilities, but we also felt that the pharmacist's specific role in a given scenario could potentially limit how much a pharmacist can actually be held accountable for.

Specialty pharmacy and specialized pharmacy services {#sec1.4}
----------------------------------------------------

A steadily increasing number of medications getting approved are complex to manage and/or require more specialized care and resources, thereby warranting an appropriate use of the term "specialty medications." Patients need pharmacists who are interested in pursuing additional education and training with these novel medications. In addition, the establishment of specialty pharmacies and/or the incorporation of specialty pharmacy services into existing practices can also help meet patients' needs. However, this seemingly benign term can result in substantial barriers for patients, including higher out-of-pockets costs and restrictions on where to obtain the medication(s). Furthermore, the use of restrictive specialty pharmacy networks and/or manufacturer distribution removes the patient's choice in this matter, in addition to further fragmenting the patient's care. Ultimately, it should be the patient's right to obtain his or her medications from the source he or she chooses.

In addition to the policies proposed by the 2019--2020 APhA Policy Committee, 15 New Business Items (NBIs) were also considered. Of these, 3 NBIs were submitted by APhA--APPM and passed in the House. These topics included: E-prescribing standardization, Community-based pharmacists as providers of care, and Integrated Nationwide Prescription Drug Monitoring program. Because of the abundance of policy items, highlighted below are a handful of policies that were discussed the most by our delegation.

Community-based pharmacists as providers of care {#sec1.5}
------------------------------------------------

Our health care system is ill-equipped to serve a large volume of people in a timely and efficient manner, without utilizing every available member of the health care team to their fullest potential, including the pharmacists. Community-based pharmacists are conveniently located and frequently offer extended hours at times when traditional clinics are closed. Rather than instinctively referring all patients to an already crowded emergency room, a more cost-effective approach may be to triage the patient at the local community pharmacy. While not every medical condition will be within the pharmacist's expertise, there are some chronic conditions and acute ailments that pharmacists can safely and effectively assess and treat. This forward-thinking policy is a conversation starter for operationalizing this patient care model. As an example, the U.S. Department of Health & Human Services recently authorized pharmacists to order and administer COVID--19 testing.[@bib5] However, to ensure practice sustainability and continued patient access, appropriate remuneration for the pharmacist's clinical assessment is critical, in addition to more flexibility in laws and regulations.

Coordination of the pharmacy and medical benefit {#sec1.6}
------------------------------------------------

The U.S. health insurance system continues to function in 2 isolated silos: the medical benefit and the pharmacy benefit, with pharmacists straddling both sides. This traditional health insurance mindset does not easily accommodate pharmacist interventions, which often show an increase in spending on medications, which is offset of a larger decrease in the overall direct health care costs. Why should a prescription drug plan foot the bill when the company underwriting the medical benefit is reaping the benefit?

If the pharmacy and medical benefits were coordinated together, health care dollars can be saved and focused on improving patient outcomes, so long as patients maintain the right to choose their providers for these benefits.

Pharmacy technicians' role in immunization administration {#sec1.7}
---------------------------------------------------------

This topic certainly garnered a lot of discussion among the APhA--APPM delegation. The profession has worked very hard to validate pharmacists' role in this public health space to the point where pharmacist-administered vaccines are now a societal norm. However, the pharmacist's expertise is best leveraged during the decision-making process for which vaccines are indicated and for the management of anaphylactic emergencies. The administration of the actual injection does not require clinical oversight.

As a corollary example, the physician evaluates a patient's candidacy for a vaccine, but it is the medical assistant who actually administers the injection.[@bib6] If pharmacists are going to take on more responsibilities as health care providers fully integrated within the care team, we will not be able to do it all, and the skillset of the whole pharmacy team needs to be leveraged appropriately.

Protecting pharmacy personnel during public health crisis {#sec1.8}
---------------------------------------------------------

During the early days of the COVID--19 crisis, pharmacy teams across the country were frequently operating without implementing significant protection and control measures. In the weeks following the approval of this policy, there appears to be significant improvements on this front. APhA should continue to solicit input from individual members to ensure that the requests outlined in this policy are appropriately honored.

Pharmaceutical safety and access during emergencies {#sec1.9}
---------------------------------------------------

At the time this article was written, Food and Drug Administration (FDA) had already issued warning letters in response to 50 different products that are either unapproved or asserting false or misleading claims, and this number is increasing daily.[@bib7] Likewise, as diagnostic tests, treatments, and an eventual vaccine become available, the demand for these products will be immense, and it is essential to protect patients from price gouging.

Although it is certainly much more fun to listen to other's perspectives, live during the open hearings and sit in the large ballroom to see the policy-making process in action, we are truly fortunate to be able to still accomplish the work of the House while remaining safe in our homes during the ongoing pandemic.
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